[Smoking cessation in smokers with pulmonary Langerhans cell histiocytosis - considerations from the management of ten patients].

Rev Mal Respir

Hôpital de la Croix-Rousse, Institut Rhône-Alpes-Auvergne de Tabacologie (IRAAT), Hôpital de la Croix- Rousse, 69004 Lyon, France.

Published: February 2021

Pulmonary Langerhans cell histiocytosis (PLCH) belongs to the spectrum of diffuse interstitial cystic pneumonias; it affects young people of both sexes and occurs almost exclusively in tobacco smokers or co-users of tobacco and cannabis. The management of this severe chronic disease is undertaken in specialized centers. A better understanding of the pathogenic mechanisms of the disease has opened up prospects for targeted therapies. However, supporting the abstinence from inhaling noxious materials which determine its prognosis remains the cornerstone of treatment. Patients with PLCH who persist in smoking despite the diagnosis may be very dependent on tobacco, experience significant difficulties in stopping smoking, and must have access to specialist smoking cessation clinics.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmr.2020.10.005DOI Listing

Publication Analysis

Top Keywords

pulmonary langerhans
8
langerhans cell
8
cell histiocytosis
8
[smoking cessation
4
cessation smokers
4
smokers pulmonary
4
histiocytosis considerations
4
considerations management
4
management ten
4
ten patients]
4

Similar Publications

Erdheim-Chester disease (ECD) is an extremely rare non-Langerhans cell disorder that is believed to include both inflammatory and neoplastic characteristics. It is caused due to genetic mutations in proto-oncogenes like BRAF and MEK, while immunological pathways have an essential role in the onset and progression of the disease. Despite its rarity, ECD poses significant diagnostic and therapeutic challenges due to its heterogeneous clinical presentation and limited understanding of its underlying pathophysiology.

View Article and Find Full Text PDF

X-linked lymphoproliferative disease (XLP) is a rare primary immunodeficiency with susceptibility and vulnerability to Epstein-Barr virus (EBV) infection. Most patients were diagnosed in early childhood and do not survive into adulthood. Here we reported an adult-onset XLP patient presenting with fever, dyspnea, and pulmonary nodules, mimicking respiratory infection at disease onset.

View Article and Find Full Text PDF

The patient was a 57-year-old man who developed bilateral thigh pain and chest tightness one year ago. Chest CT scan showed reticular shadows, thickened interlobular septa in both lung fields, and pericardial effusion. Three months ago, his symptoms worsened.

View Article and Find Full Text PDF

Introduction: Adult spinal Langerhans cell histiocytosis (LCH) presents a treatment challenge due to ongoing controversies. Traditional approaches such as curettage with bone grafting and internal fixation are preferred for severe cases involving mechanical instability, neurological deficits, or deformity. This study aimed to explore the efficacy of a customized approach involving simple posterior instrumentation without curettage or bone grafting in treating adult spinal LCH.

View Article and Find Full Text PDF

Pulmonary Langerhans cell histiocytosis (PLCH) in adults is an uncommon disorder that occurs almost exclusively in smokers. PLCH has no known gender predilection, and the current consensus of its true aetiology is unknown. Lungs may the sole organ involved, however other organs in the body may be involved as well.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!